Literature DB >> 26947384

Sex Difference in Chest Pain After Implantation of Newer Generation Coronary Drug-Eluting Stents: A Patient-Level Pooled Analysis From the TWENTE and DUTCH PEERS Trials.

Marlies M Kok1, Liefke C van der Heijden1, Hanim Sen1, Peter W Danse2, Marije M Löwik1, Rutger L Anthonio3, J Hans W Louwerenburg1, Frits H A F de Man1, Gerard C M Linssen4, Maarten J IJzerman5, Carine J M Doggen5, Angela H E M Maas6, Roxana Mehran7, Clemens von Birgelen8.   

Abstract

OBJECTIVES: This study sought to assess sex differences in chest pain after percutaneous coronary intervention (PCI) with newer generation drug-eluting stents (DES).
BACKGROUND: Sex-based data on chest pain after PCI with DES are scarce.
METHODS: The authors performed a patient-level pooled analysis of the TWENTE and DUTCH PEERS randomized trials, in which patients were treated with newer generation permanent polymer-coated DES. At 1 and 2 years, clinical follow-up was available in 99.8% and patient-reported chest pain data in 94.1% and 93.6%, respectively.
RESULTS: Among all 3,202 patients, the 871 (27.2%) women were older (67.5 ± 10.2 years vs. 62.8 ± 10.6 years; p < 0.001) and had more cardiovascular risk factors: diabetes (24.2% vs. 17.8%; p < 0.001), hypertension (63.6% vs. 51.6%; p < 0.001), and positive family history (54.5% vs. 50.1%; p = 0.03). At 1- and 2-year follow-up, women reported more clinically relevant chest pain (16.3% vs. 10.5%; p < 0.001, and 17.2% vs. 11.1%; p < 0.001, respectively). Multivariate analysis demonstrated that female sex independently predicted clinically relevant chest pain at 1- and 2-year follow-up both during daily activities and at minimum physical exertion/at rest (1 year adjusted odds ratio [OR]: 1.7; 95% confidence interval [CI]: 1.2 to 2.4; p = 0.002; and adjusted OR: 1.8; 95% CI: 1.3 to 2.5; p < 0.001; 2-year adjusted OR: 1.8; 95% CI: 1.3 to 2.6; p < 0.001; and adjusted OR: 1.7; 95% CI: 1.3 to 2.3; p = 0.001). Nevertheless, the 2-year rates of death, myocardial infarction, revascularization, stent thrombosis, and various composite clinical endpoints were similar for both sexes.
CONCLUSIONS: Although the incidence of adverse cardiovascular events was low and similar for both sexes, women showed a statistically significantly higher prevalence of clinically relevant chest pain, which might be largely related to mechanisms other than epicardial coronary obstruction.
Copyright © 2016 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  chest pain; newer generation drug-eluting stent(s); percutaneous coronary intervention; randomized clinical trial; second-generation drug-eluting stent(s); sex analysis

Mesh:

Year:  2016        PMID: 26947384     DOI: 10.1016/j.jcin.2015.10.043

Source DB:  PubMed          Journal:  JACC Cardiovasc Interv        ISSN: 1936-8798            Impact factor:   11.195


  6 in total

1.  Ischemic Heart Disease in Women: Not About Religion.

Authors:  Angela Hem Maas
Journal:  Eur Cardiol       Date:  2017-08

Review 2.  Sex-Specific Outcomes in Cardiovascular Device Evaluations.

Authors:  Mohammed Imran Ghare; Daniela Tirziu; Jinnette Dawn Abbott; Elissa Altin; Yiping Yang; Vivian Ng; Cindy Grines; Alexandra Lansky
Journal:  J Womens Health (Larchmt)       Date:  2020-06-15       Impact factor: 3.017

Review 3.  Self-management of cardiac pain in women: an evidence map.

Authors:  Monica Parry; Ann Kristin Bjørnnes; Hance Clarke; Lynn Cooper; Allan Gordon; Paula Harvey; Chitra Lalloo; Marit Leegaard; Sandra LeFort; Judith McFetridge-Durdle; Michael McGillion; Sheila O'Keefe-McCarthy; Jennifer Price; Jennifer Stinson; J Charles Victor; Judy Watt-Watson
Journal:  BMJ Open       Date:  2017-11-25       Impact factor: 2.692

4.  Patient preference for radial versus femoral vascular access for elective coronary procedures: The PREVAS study.

Authors:  Marlies M Kok; Marieke G M Weernink; Clemens von Birgelen; Anneloes Fens; Liefke C van der Heijden; Janine A van Til
Journal:  Catheter Cardiovasc Interv       Date:  2017-05-04       Impact factor: 2.692

5.  Coronary magnetic resonance imaging after routine implantation of bioresorbable vascular scaffolds allows non-invasive evaluation of vascular patency.

Authors:  Constantin von Zur Mühlen; Simon Reiss; Axel J Krafft; Lisa Besch; Marius Menza; Manfred Zehender; Timo Heidt; Alexander Maier; Thomas Pfannebecker; Andreas Zirlik; Jochen Reinöhl; Peter Stachon; Ingo Hilgendorf; Dennis Wolf; Philipp Diehl; Tobias Wengenmayer; Ingo Ahrens; Christoph Bode; Michael Bock
Journal:  PLoS One       Date:  2018-01-25       Impact factor: 3.240

6.  Development and usability testing of HEARTPA♀N: protocol for a mixed methods strategy to develop an integrated smartphone and web-based intervention for women with cardiac pain.

Authors:  Monica Parry; Abida Dhukai; Hance Clarke; Ann Kristin Bjørnnes; Joseph A Cafazzo; Lynn Cooper; Paula Harvey; Joel Katz; Chitra Lalloo; Marit Leegaard; France Légaré; Mike Lovas; Judith McFetridge-Durdle; Michael McGillion; Colleen Norris; Laura Parente; Rose Patterson; Louise Pilote; Leah Pink; Jennifer Price; Jennifer Stinson; Akib Uddin; J Charles Victor; Judy Watt-Watson; Carol Auld; Christine Faubert; Deborah Park; Marianne Park; Beatrice Rickard; Vincenza Spiteri DeBonis
Journal:  BMJ Open       Date:  2020-03-09       Impact factor: 2.692

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.